The Pasteur Museum is housed in the apartment where Louis Pasteur spent his final seven years and offers a rare behind-the-scenes look at the living and working environment of the world-renowned scientist. Visitors can gain a unique insight into his everyday life alongside his wife and can admire his rich and diverse scientific work.
The Institut Pasteur’s scientific strategy focuses on developing original and innovative topics and promoting interdisciplinary and multidisciplinary cooperation and approaches. The Institut Pasteur teams have access to the technological resources needed to speed up and further improve the quality of their outstanding research.
Ever since the introduction of the world’s first "Technical Microbiology" course in 1889, teaching has been a priority for the Institut Pasteur. The Institut Pasteur has an international reputation for quality teaching that attracts students from all over the world who come to further their training or top up their degree programs.
The mission of the Industrial Partnership team is to detect, promote, assist and protect the inventive activities from research (inventions, know-how and biological materials) conducted at the Institut Pasteur (and in some Institutes of its international network), and transfer there to industrial and/or institutional partners, in order to serve the patient needs and for the benefit of the society, as well as to contribute to sustainability of the Institut Pasteur’s resources.
With international courses, PhD and postdoctoral traineeship, each institute of the Institut Pasteur International Network (RIIP) contributes to the transmission of knowledge with the training of young researchers all around the world. In this context, doctoral and postdoctoral programmes, study and traineeship fellowships are available to scientists. Alongside training, dynamism and attractiveness of RIIP will result in the creation of 4-year group for the young researchers.
The Institut Pasteurpromotes entrepreneurship with the aim that the creation of new companies from Institut Pasteur laboratories should in the future play an important role in disseminating cutting-edge innovative technologies derived from the campus.
(Created in 2010)
Affilogic is a biotech company developing a new class of proprietary affinity ligands: Nanofitins®. Nanofitins® are able to selectively bind a wide range of targets and have proven excellent tools for: Targeting (immunolocalization, in vivo neutralization), Capture (affinity chromatography, protein removal…), Detection (immunoassays, Western Blot…). Nanofitins® constitute a robust and affordable alternative to antibodies.
Anaconda Pharma ("Anaconda") has developed a proprietary technology platform that allows to discover drugs that inhibit protein/protein interactions ("PPI"). The company has initially applied its technology to develop drugs to treat Human Papillomavirus ("HPV")-related diseases. Anaconda originated in The Pasteur Institute ans UC Berkeley and is incorporated and headquartered in Paris, France.
Ariana™ Pharma delivers intelligent tools to dramatically improve decision-making in the fields of discovery, development and safety for the pharmaceutical industry. Its KEM® knowledge extraction and management system comprehensively mines data, identifying relations that other systems neglect, and helps scientists take decisions involving a wide range of criteria and objectives.
Axenis is a company providing preclinical research services. After more than 15 years of research and development at the Institut Pasteur, Erwan Corcuff, the CEO, offers know-how and unique models for industrial preclinical studies.
CELLECTIS SA was founded as a spin-off from the Institut Pasteur. It is the first company to apply the Meganuclease Recombination System approach to in vivo genome engineering. Cellectis is focused on the research and development of novel Meganucleases for genome intervention and provides tools for in vivo site directed recombination.
Genomic Vision is a biotechnology company that combines pioneering Molecular Combing, a proprietary single DNA molecule detection technology, with biomarker discovery to develop and commercialize novel genetic tests and research tools for life science. Genomic Vision’s products focus on DNA analysis and genetic testing in the fields of cancer, rare inherited disorders and pharmacogenomics.
Genticel is a bio-pharmaceutical company, created in 2001 and spun out from the Institut Pasteur in 2002. The company strives to improve the well-being of people through the development of therapeutic vaccines for infection, dysplasia and cancer provoked by the Human Papillomavirus (HPV).
Hybrigenics is a bio-pharmaceutical company listed (ALHYG) on Alternext (NYSE-Euronext) in Paris, focusing its internal R&D programs on innovative targets and therapies for the treatment of proliferactive cancerous or non-cancerous diseases. Hybrigenics’ current development program is based on inecalcitol, a vitamin D receptor agonist active by oral administration.
Pierre Langlade-Demoyen and Simon Wain-Hobson have created Invectys, a company engaged in the development of a very promising new therapeutic cancer vaccine based upon an original “telomerase DNA technology”. The basic scientific research demonstrates a particularly promising reaction to the treatment, and a hope of potential treatment of a broad array of cancers.
Pathoquest SAS is a distinctive new generation Molecular Diagnostics company that offers a game changing approach using the combination of disruptive NGS (Next Generation Sequencing) and Bioinformatics / Database tools.
(Created in January 1987)
Texcell is a world-renowned company that provides high-quality biosafety and immunology services for bioproducts in full compliance with GLP and GMP standards. With 25 years experience, they have tested and validated products now licensed by the FDA and the EMEA (e.g. monoclonal antibodies, recombinant proteins, viral vaccines, human plasma products, biological APIs, gene therapy and cell therapy products). Texcell provides viral safety testing, virus validation and immunoprofiling.
THERAVECTYS is a clinical development-stage biotechnology company with a novel vaccine platform that can be applied to the treatment and prevention of a broad range of infectious diseases, cancers, and other diseases and conditions. Research and development activities are based on 15 years of research conducted at the Pasteur Molecular Virology and Vectorology laboratories.